Predicting drug disposition via application of a biopharmaceutics drug disposition classification system

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 162-167

  Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARRIER PROTEIN; CEFADROXIL; CEFRADINE; CYTOCHROME P450 3A; FEXOFENADINE; GEMCITABINE; GLYCOPROTEIN P; LEVOFLOXACIN; LORACARBEF; OFLOXACIN; PREGABALIN; ROSUVASTATIN; SOTALOL; TELMISARTAN;

CLASSIFICATION ALGORITHM; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BIOPHARMACEUTICS; CARRIER PROTEINS; FORECASTING; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 77149165406     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00498.x     Document Type: Conference Paper

References (28)

1. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992 52 : 453 457.
2. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995 58 : 15 9.
3. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995 58 : 492 497.
4. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997 62 : 41 9.
5. Hebert MF, Fisher RM, Marsh CL, Dressler D, Berkersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999 39 : 91 6.
6. Floren LC, Christians U, Zimmerman JJ, Neefe L, Schorer R, Rushworth D et al. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole. Clin Pharmacol Ther 1999 65 : 159.
7. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharm Res 2005 22 : 11 23.
8. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995 12 : 413 420.
9. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administation, Rockville, MD, 2000. Retrieved from http://www.fda.gov/cder/ guidance/index.htm.
10. Chen ML, Yu L. The use of drug metabolism for prediction of intestinal permeability (dagger). Mol Pharmaceut 2009 6 : 74 81.
11. Larregieu CA, Benet LZ. Use of drug metabolism and Caco-2 transport for prediction of intestinal permeability revisited using accepted scientific definitions vs. an FDA surrogate. Mol Pharmaceut 2009 In press).
12. Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP et al. The use of BDDCS in classifying the permeability of marketed Drugs. Pharm Res 2008 52 : 483 488.
13. European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/WEP/QWP/1401/98. European Medicines Agency Web site (July 2008). 2008: Retrieved from http://www.emea.europa.eu/pdfs/human/qwp/ 140198enrev1.pdf.
14. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Clin Pharmacokinet 2001 40 : 159 168.
15. Wu C-Y, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab Dispos 2003 31 : 1292 1295.
16. Lau YY, Wu C-Y, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004 308 : 1040 1045.
17. Benet LZ, Cummins CL, Wu C-Y. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003 4 : 393 398.
18. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995 13 : 129 134.
19. Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006 316 : 762 771.
20. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006 34 : 1175 1181.
21. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007 81 : 194 204.
22. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999 27 : 866 871.
23. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008 36 : 796 805.
24. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008 36 : 2014 2023.
25. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998 15 : 1154 1159.
26. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharmaceut 2005 2 : 157 167.
27. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009 26 : 2039 2054.
28. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008 60 : 717 733.